Search Medical Condition
Please enter condition
Please choose location

Izmir, Bornova Clinical Trials

A listing of Izmir, Bornova clinical trials actively recruiting patients volunteers.

RESULTS

Found (97) clinical trials

Patients should be in need of and fit for immunochemotherapy and should not be resistant to rituximab (resistance defined as lack of response, or progression within 6 months of the last course of treatment with a rituximab containing regimen). This study will be composed of two parts: Safety run-in and ...

Phase

This study is designed to evaluate progression-free survival for ACE-196 vs ibrutinib in previously treated chronic lymphocytic leukemia. Intervention: ACP-196 will be orally administered until disease progression or unacceptable toxicity. Ibrutinib will be orally administered until disease progression or unacceptable toxicity. Study Type: Interventional Study Design: Allocation: Randomized Intervention Model: ...

Phase

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

This is an event driven study to reach statistical power given all other assumptions. Subjects will visit the clinic 1 month after randomization and at regular intervals thereafter. Additionally, for any subject prematurely discontinuing study medication, assessments will be conducted every 6 months for the collection of study endpoints. Those ...

Phase

Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates

Neonates and infants aged less than 6 months who pass the screen of in- and exclusion criteria, who have been treated for at least five days with heparin and /or VKA for confirmed symptomatic or asymptomatic arterial or venous thrombosis are eligible for the study. Study treatment consists of a ...

Phase

Efficacy Safety Pharmacodynamic and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

The total duration per patient is at least 3 years and up to 5 years and 3 months. This includes up to approximately two month of screening, 52 weeks of primary analysis period, up to 4 years of extension treatment period, an end-of- study visit within 2 weeks of the ...

Phase